The Next Biggest Winner
Chris Moreau of Miraculins
"Miraculins is an emerging biotechnology company committed to extending life, reducing suffering and lowering healthcare costs. Through our leadership in the development and commercialization of diagnostic tests, we strive to improve the overall diagnosis and treatment of patients by enhancing the information available to physicians"The Miraculins advantage
Miraculins focuses on in-licensing/acquiring and developing both cancer and non-cancer diagnostic opportunities that have completed early stage research and address unmet clinical needs.Miraculins’ internal research program has lead to the discovery and identification of prostate cancer biomarkers, the lead marker of which is called Prostate Secretory Protein or PSP94. Miraculins also acquired several biomarkers in the areas of Gastric, Colorectal, and Pancreatic Cancer and are in the process of moving those programs further through the pipeline.
With the experience gained from developing its first assay, and the addition of a strong scientific team, Miraculins has developed a process and criteria for evaluating technologies as potential licensing targets.Once Miraculins has determined that a specific technology meets its criteria the Company adds value to the early stage research by developing a clinical grade assay, confirming the diagnostic potential of the technology and moving the test through to regulatory approval and commercial sales.
Miraculins therefore bridges the gap between early stage research, completed at the university/institution level, and clinical grade commercial assays.Under its new business model, Miraculins has acquired a panel of Preeclampsia biomarkers from Mount Sinai Hospital and partnered the program with Inverness Medical Innovations (NYSE:IMA), one of the world’s largest diagnostic companies.
With the experience gained from developing its first assay, and the addition of a strong scientific team, Miraculins has developed a process and criteria for evaluating technologies as potential licensing targets.Once Miraculins has determined that a specific technology meets its criteria the Company adds value to the early stage research by developing a clinical grade assay, confirming the diagnostic potential of the technology and moving the test through to regulatory approval and commercial sales.
Miraculins therefore bridges the gap between early stage research, completed at the university/institution level, and clinical grade commercial assays.Under its new business model, Miraculins has acquired a panel of Preeclampsia biomarkers from Mount Sinai Hospital and partnered the program with Inverness Medical Innovations (NYSE:IMA), one of the world’s largest diagnostic companies.
Learn more about Miraculins
Visit their website @ www.miraculins.com
CONTENT POSTED ON THIS BLOG DOES NOT CONSTITUTE A BUY OR SELL RECOMMENDATION. MANY OF THE COMPANIES PROFILED HERE I AM NOT INVESTED IN AND DO NOT INTEND TO INVEST IN. THESE ARE MERELY MY THOUGHTS ON MARKET CONDITIONS AND STOCK VALUATIONS. INVESTING IN THE STOCK MARKET CAN BE VERY RISKY AND YOU SHOULD ALWAYS CONSULT AN INVESTMENT PROFESSIONAL BEFORE MAKING ANY DECISIONS. ULTIMATELY YOU ARE RESPONSIBLE FOR CONDUCTING YOUR OWN DUE DILIGENCE AND PROTECTING YOUR MONEY.
Visit their website @ www.miraculins.com
CONTENT POSTED ON THIS BLOG DOES NOT CONSTITUTE A BUY OR SELL RECOMMENDATION. MANY OF THE COMPANIES PROFILED HERE I AM NOT INVESTED IN AND DO NOT INTEND TO INVEST IN. THESE ARE MERELY MY THOUGHTS ON MARKET CONDITIONS AND STOCK VALUATIONS. INVESTING IN THE STOCK MARKET CAN BE VERY RISKY AND YOU SHOULD ALWAYS CONSULT AN INVESTMENT PROFESSIONAL BEFORE MAKING ANY DECISIONS. ULTIMATELY YOU ARE RESPONSIBLE FOR CONDUCTING YOUR OWN DUE DILIGENCE AND PROTECTING YOUR MONEY.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.